EPNS 2022 poster: Comparing the change in 6-minute walk distance in nmDMD patients receiving ataluren: STRIDE Registry compared with Phase 3 clinical trial
View an analysis of motor function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in real-world practice versus a clinical trial setting in our poster presented at EPNS 2022
Read about the baseline demographics and characteristics of patients with nmDMD from the 2 study populations
Review the motor function outcomes, as determined by the results of the 6-minute walk test, for patients treated with a mutation-specific DMD therapy from both studies
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200144 | June 2022
Sign in or register to access exclusive content on this site